Cipla Subsidiary InvaGen Receives NAI Classification from USFDA for New York Facility
Cipla Ltd 路 Others (Uncategorized) 路 18 Nov 2026, 4:48 am
Cipla Subsidiary InvaGen Receives NAI Classification from USFDA for New York Facility Cipla announced that the USFDA has classified the inspection of its wholly owned subsidiary InvaGen Pharmaceuticals Inc.'s manufacturing facility in Hauppauge, Long Island, New York, as No Action Indicated (NAI). The inspection was conducted between 19th Oct'26 and 22nd Oct'26, with the USFDA communicating the NAI classification on 17th Nov'26.
Original exchange filing (PDF)
More announcements from Cipla Ltd
- Please find enclosed disclosure. 路 17 Nov 2026
- Appointment of Mr Vikram Janakiraman, as the Global Chief Technical Operating Officer, designated as a Senior Management Personnel of the Company, with effect from 7th December, 2026. 路 04 Nov 2026
- Please find enclosed Earnings Call Transcript - Q2FY27 路 30 Oct 2026
- In compliance with the provisions of Regulation 30 of SEBI (LODR) Regulations, 2015, we hereby notify that the Operations and Administrative Committee of the Company on 29th October, 2026 .... 路 30 Oct 2026
- Pursuant to Regulation 30 read with Part A of Schedule III and Regulation 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the audio recording of the .... 路 28 Oct 2026
- Please find intimation in relation to grant of ESOS and ESAR. 路 27 Oct 2026
- Please find enclosed the intimation for Appointment of Ms Rashmi Joshi as an additional and independent director of the Company w.e.f. 27th October, 2026 for a period of 5 years. 路 27 Oct 2026
- Please find enclosed the intimation for appointment of Ms Rashmi Joshi as an additional and independent director of the company w.e.f. 27th October, 2026 for a period of 5 years. 路 27 Oct 2026
